Frank ZhangCEO at Syneron Biotechnology (Shanghai) Co., Ltd.Presenter
Profile
Syneron Tech, founded in April 2022, is committed to combining generative artificial intelligence with high-throughput experimental technology to independently develop synthetic peptide drugs for undruggable targets with huge clinical needs. The core team is composed of first-class talents with rich experience in the fields of biomedicine, artificial intelligence, investment and financing: CEO, Dr. Zhang Xiao has rich experience in the financing and operation of Biopharmaceutical enterprises, and was a partner of CEC Capital before starting his business, and has completed more than 40 billion yuan of financing transactions for more than 60 domestic and foreign biotechnology companies. Professor Xin Gao, the CAIO, is the Director of the Center for Computational Biology at King Abdullah University of Science and Technology in Saudi Arabia, and is a leading scientist at the intersection of artificial intelligence and biology, with more than 320 academic papers and a total impact factor of more than 1,500. Dr. Yan Degenhardt, the CSO, has worked at GSK United States R&D Center for 17 years and is a senior scientific director of oncology, responsible for the development of multiple global first-in-class anticancer drugs from target validation to clinical stage. Another co-founder, Professor Pei Dehua, is a global leading scientist in the field of penetrating peptides, a tenured professor at Ohio State University in United States, and a former scientific founder of Entrada Therapeutics, a United States-listed biotechnology company.